This multi-site, Phase 2 clinical trial is an open-label study to identify the safety,
pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for
the treatment of patients with residual high-grade meningioma following resection surgery,
radiographically-confirmed progression of high-grade meningioma or recurrent high-grade
meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable
patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle for
up to twelve cycles, until disease progression or death, whichever occurs first. Following
the completion of cycle twelve, patients receiving benefit will be given the option to
continue receiving compassionate use treatment with NEO100.
Residual, Progressive or Recurrent Grade II or III Meningioma
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.